ZTS · Zoetis Inc.

184 filings

8-K

ZTS 8-K Current Reports

Zoetis Inc. - 184 current reports

Filing record · 2016–202610-K1110-Q338-K135

Showing 1-50 of 184 filings

8-K

Leadership ChangesRegulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Oct 13, 2026)

Zoetis Inc. (NYSE: ZTS) filed a Form 8-K on October 13, 2026 disclosing the appointment of Iris Knobloch to its Board of Directors, effective December 1, 2026. Under Item 5.02, the Board appointed Ms. Knobloch on October 8, 2026, to serve on the Corporate Governance Committee, and the Board size will expand from twelve to thirteen members. The filing states she was not selected under any arrangement with a third party and has no reportable related-party transactions. She will receive the standard non-employee director compensation and enter into the Company's standard indemnification agreement. The appointment is a governance event rather than a financial one. The filing contains no financial results, guidance, M&A activity, or changes to executive management, and it does not affect Zoetis's reported financials or operations. Investors should view it as routine board refreshment, with the most notable element being the addition of a director with consumer, digital, and international media experience to a company in animal health. Ms. Knobloch's current board seats at Deezer, Lazard, and Vail Resorts, along with her past roles, could be relevant to how the board addresses consumer strategy and digital initiatives. The Company's CEO, Kristin Peck, and Board Chair, Michael McCallister, both praised the appointment, linking it to the Company's innovation strategy, customer engagement, and new ways to reach pet owners. The Item 7.01 press release is furnished, not filed, and carries no material new financial information. Overall, the filing is low-impact for near-term valuation and fundamentals.

Oct 13, 2026 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 8, 2026)

Zoetis Inc. (ZTS) has announced a quarterly dividend payment of $0.53 per share for the fourth quarter of 2026. This declaration, made on October 8, 2026, signals continued commitment to returning capital to shareholders. The dividend is scheduled to be paid on December 1, 2026, to shareholders of record as of October 30, 2026. This information is being disclosed under Regulation FD and is accompanied by a press release. While this filing focuses solely on the dividend declaration and does not provide updates on financial performance or strategic initiatives, it represents a regular step in Zoetis' capital allocation strategy. Investors seeking to participate in this dividend should ensure their holdings are registered by the specified record date. The company has also included the standard cover page interactive data file in its filing.

Oct 8, 2026 8-K

Leadership ChangesExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Aug 6, 2026)

Zoetis (ZTS) announced that James "Jay" Saccaro will become Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. The role is newly created and combines the global finance function (capital allocation, financial strategy, reporting and controls, investor engagement) with oversight of Global Manufacturing and Supply. Saccaro will be the principal financial and principal accounting officer. He comes from GE HealthCare, where he has been CFO since June 2023, and previously spent roughly eight years as CFO of Baxter International. The 8-K also reports a planned CFO transition: Wetteny Joseph, the current EVP and CFO, will step down from the executive role after August 16, 2026 and remain a non-executive officer until the earlier of February 28, 2027 or a mutually agreed date. The company states his departure was not due to any disagreement on operations, policies, practices, accounting, or internal controls. Saccaro's compensation package includes a $1,000,000 base salary, a 100% of salary target bonus (2026 paid at target and pro-rated), and a $5,000,000 annual long-term incentive target (50% PSUs, 25% RSUs, 25% stock options). He also receives a one-time make-whole RSU award with a $6,250,000 grant-date value vesting in thirds over three years, plus a $1,250,000 one-time cash award subject to repayment if he is terminated under certain circumstances within his first year. Joseph will keep his base salary, benefits and equity vesting through his termination date, may earn a 2026 annual incentive at target subject to company performance funding, and will receive Executive Severance Plan benefits on departure. His outstanding equity will be treated as a Restructuring Event. For investors, the key points are continuity of finance leadership through a planned handover and the expanded mandate, which places manufacturing and supply under the CFO and signals a focus on operational execution alongside capital allocation. The filing does not discuss financial results or guidance changes. The make-whole awards and the planned CEO-level reporting of Joseph as a special advisor on financial matters through early 2027 suggest a deliberately managed transition rather than an abrupt departure.

Aug 6, 2026 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Aug 6, 2026)

Zoetis reported second quarter 2026 results on August 6, 2026, with revenue flat year over year at $2.5 billion ($2,468 million) on a reported basis and down 1% on an organic operational basis. GAAP net income was $691 million, or $1.65 per diluted share, down 5% in dollars but up 1% per share thanks to a lower share count (417.7 million diluted shares versus 445.5 million a year earlier). Adjusted net income was $781 million, or $1.87 per diluted share, down 2% organically. The quarter was dominated by weakness in the U.S. Companion Animal business, where revenue fell 11% on softer end-market demand, pricing pressure on the dermatology franchise and Simparica Trio, and generic competition for Cerenia and Convenia. Livestock (up 23% in the U.S.) and International growth (up 6% organically) partly offset the decline. The more significant news for investors is the guidance cut. Full-year 2026 revenue guidance was lowered to $9.120-$9.320 billion, implying organic operational growth of (3)% to (1)%, down from the prior 2% to 5% range given in May. Adjusted diluted EPS guidance was reduced to $6.15-$6.25 from $6.85-$7.00, and reported diluted EPS guidance to $5.55-$5.65 from $6.35-$6.50. Management attributed the revision to a more pressured Companion Animal market, including lower clinic visits, pet owner price sensitivity, and heightened competition. The company also flagged higher restructuring and cost-reduction charges, with certain significant items and acquisition-related costs now expected to total about $150 million, up from $100 million. Management is responding with targeted commercial investments, accelerated innovation, and business development. The company highlighted new approvals and launches, including Lenivia and Portela (long-acting osteoarthritis pain antibodies), Dectomax-CA1 as the first FDA conditional approval for New World screwworm, and the VitalRADS teleradiology acquisition. Investors should weigh these pipeline and diversification efforts against near-term earnings pressure, the sharp guidance reduction, and the ongoing Companion Animal headwinds.

Aug 6, 2026 8-K

Leadership ChangesShareholder Matters

Zoetis Inc. 8-K Report, Executive Changes (May 22, 2026)

Zoetis Inc. (ZTS) filed an 8-K on May 22, 2026, reporting on its 2026 Annual Meeting of Shareholders held on May 20, 2026. The filing details the outcomes of five proposals voted on by shareholders, with a notable 90.13% of outstanding shares represented, indicating strong shareholder engagement. The meeting also marked the retirement of Ms. Louise M. Parent from the Board of Directors in accordance with the company's retirement policy. Key outcomes include the overwhelming re-election of all twelve director nominees, demonstrating continued confidence in the board's leadership. Shareholders also approved, on an advisory basis, the executive compensation program and affirmed the preference for an annual advisory vote on executive compensation. The appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2026 was ratified. However, a shareholder proposal to permit action by written consent was not approved.

May 22, 2026 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 20, 2026)

Zoetis Inc. (ZTS) has announced a quarterly dividend of $0.53 per share for the third quarter of 2026. This announcement, made on May 20, 2026, provides a clear income stream update for its shareholders. The dividend payment is scheduled for September 1, 2026, with a record date of July 20, 2026, ensuring that investors holding the stock by mid-July will be eligible to receive this payout.

May 20, 2026 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (May 7, 2026)

Zoetis (ZTS) reported first quarter 2026 results that came in below management's expectations, with the company citing a more challenging operating environment. Revenue rose 3% reported to $2.262 billion but was flat on an organic operational basis. Reported net income was $601 million ($1.42 diluted EPS), while adjusted net income reached $646 million ($1.53 adjusted diluted EPS, up 9% reported and 7% organic operational). The U.S. segment was a clear weak spot, with revenue down 8% driven by an 11% decline in companion animal sales from competitive pressure in dermatology and Simparica Trio, pet owner price sensitivity, lower veterinary visits, generic competition on Convenia and Cerenia, and lower Librela sales. International revenue grew 17% reported (10% organic operational), and livestock grew 15% reported, partly helped by an estimated $100 million benefit from the Fiscal Year Alignment and timing of price increases. Management lowered full-year 2026 guidance. Revenue is now expected at $9.680 to $9.960 billion (2% to 5% organic operational growth), adjusted net income at $2.870 to $2.950 billion (2% to 6% organic growth), and adjusted diluted EPS at $6.85 to $7.00. Reported diluted EPS guidance is $6.35 to $6.50. Investors should note that the Fiscal Year Alignment, which eliminated the one-month reporting lag for non-U.S. subsidiaries and retroactively recast prior periods, complicates year-over-year comparisons and flatters International growth in the quarter. Strategically, Zoetis continues to point to a pipeline of more than 12 potential blockbusters and a planned acquisition of Neogen's animal genomics business, expected to close in the second half of 2026. Restructuring and certain significant items totaled $27 million pre-tax in the quarter, primarily employee termination costs tied to organizational refinements, signaling ongoing cost actions alongside the commercial reset.

May 7, 2026 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Feb 12, 2026)

Zoetis reported Q4 and full-year 2025 results on February 12, 2026. For Q4, revenue rose 3% to $2.39 billion (4% organic operational growth), and reported net income rose 4% to $603 million, or $1.37 per diluted share. Adjusted diluted EPS was $1.48, up 6% on a reported basis. For full-year 2025, revenue reached $9.47 billion (up 2% reported, 6% organic operational), reported EPS was $6.02 (up 10%), and adjusted EPS was $6.41 (up 8%). Growth was led by Companion Animal, which rose 5% for the year, while Livestock declined 5% reported (up 3% organic) largely because of the divestiture of the medicated feed additive portfolio. Quality of the Q4 International beat warrants scrutiny. Management disclosed that the operational changes tied to the elimination of the one-month reporting lag (the "Expected Fiscal Year Alignment") pulled roughly 2.5% to 3.5% of International segment sales into Q4 2025, and it does not expect that effect to recur at fiscal year-end 2026. The company also shifted the timing of annual price increases in certain International subsidiaries into 2026 and delayed processing of some December 2025 orders into 2026. Investors should therefore treat part of Q4 growth as timing-driven rather than underlying demand. For 2026, Zoetis guided to revenue of $9.825 to $10.025 billion, with 3% to 5% organic operational growth, and adjusted diluted EPS of $7.00 to $7.10 (reported EPS of $6.65 to $6.75). Pipeline news included first approvals for long-acting OA pain products Lenivia (dogs) and Portela (cats) in Canada and the EU, with launches planned this year. The guidance reflects January 20, 2026 foreign exchange rates and about $65 million of expected significant items and acquisition-related costs.

Feb 12, 2026 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 5, 2026)

Zoetis Inc. (ZTS) has filed a Current Report (8-K) on February 5, 2026, primarily announcing its second-quarter 2026 dividend declaration. The company has declared a dividend of $0.53 per share, which is a positive signal to investors regarding the company's financial health and commitment to returning capital to shareholders. This dividend payment is scheduled for June 2, 2026, with a record date of April 20, 2026, providing clear timelines for eligible shareholders.

Feb 5, 2026 8-K

Material AgreementsFinancial EventsSecurities & Listing+2

Zoetis Inc. 8-K Report, Material Agreement (Dec 18, 2025)

On December 18, 2025, Zoetis completed a $2.0 billion private offering of 0.25% Convertible Senior Notes due June 15, 2029, including the $250 million over-allotment option that was exercised in full. Net proceeds are approximately $1,969.6 million. The company plans to use roughly $186.6 million for capped call transactions, $248.0 million for a privately negotiated repurchase of about 2.1 million shares, and the remaining approximately $1,535.0 million for additional open-market or privately negotiated buybacks under its existing $6 billion repurchase program, expected to be completed by Q1 2026. The effect is a large, debt-funded share repurchase that is designed to be largely offset in dilution terms by the capped calls. The notes carry a low 0.25% coupon and an initial conversion price of about $148.20, a 22.5% premium to the December 15, 2025 closing price. Zoetis has the option to settle conversions in cash, shares, or a combination, and it must pay cash at least up to principal. The capped calls, with a $211.72 cap (75% premium), cover roughly 13.5 million shares and are intended to reduce dilution up to that price. The maximum potential share issuance is about 13.5 million shares, or 16.5 million including make-whole adjustments. The notes are senior unsecured obligations, and the filing discloses a waiver under the revolving credit facility that permits early conversions. For investors, the transaction shifts the capital structure toward low-cost convertible debt and reduces the share count in the near term, which can support per-share metrics. Key risks include the added leverage of roughly $2 billion, potential hedge-related trading activity around conversion or repurchase windows, and the execution of the buyback program over the coming months. The filing is a financing and capital-allocation event rather than a change in operating performance.

Dec 18, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 11, 2025)

Zoetis Inc. (ZTS) has announced its first-quarter 2026 dividend, demonstrating a consistent commitment to returning capital to shareholders. The company declared a dividend of $0.53 per share, payable on March 3, 2026, to shareholders of record as of January 20, 2026. This regular dividend payment is a key indicator of the company's financial stability and its confidence in sustained profitability. While this filing is primarily a Regulation FD disclosure regarding the dividend, it underscores Zoetis' ongoing capital allocation strategy. Investors should view this as a positive signal of the company's financial health and its ability to generate consistent cash flows to support shareholder returns. Further analysis of Zoetis' broader financial performance, strategic initiatives, and market position would be necessary for a complete investment assessment.

Dec 11, 2025 8-K

Other EventsExhibits & Filings

Zoetis Inc. 8-K Report, Corporate Update (Dec 2, 2025)

Zoetis Inc. (ZTS) filed a Form 8-K on December 2, 2025 furnishing the presentation for its Innovation Webcast, held that morning at 8:30 a.m. ET. The filing is informational under Item 8.01 (Other Events) and contains no new financial results, guidance changes, or material agreements. Its substance is a strategic update on the company's long-term growth narrative, which management frames around a Animal Health market expected to reach roughly $90 billion by 2035, up from about $50 billion in 2024. Management's key message is that growth is being driven by two structural tailwinds: companion animal demand (premiumization, pet longevity, and advanced therapies such as JAK inhibitors and monoclonal antibodies) and livestock demand (rising protein consumption and a shift toward preventive vaccines). The presentation emphasizes Zoetis's R&D model, citing R&D investment of $686 million in 2024 (7.4% of revenue, up from $463 million in 2020), a pipeline with expected major approvals each year through the late 2020s, and new therapeutic areas in chronic kidney disease, oncology, and cardiology, which management estimates together represent $5 billion or more in total addressable market. The company reported 2024 adjusted EBITDA of $3.8 billion (41% of revenue) and adjusted net income of $2.7 billion. For investors, the filing offers management's long-term framework rather than near-term catalysts. Its forward-looking statements are extensive, and the presentation's targets (such as the $90 billion market projection and the new-market TAM figures) are internal estimates subject to regulatory, competitive, and execution risk. Investors should weigh these long-range claims against the company's upcoming quarterly results and pipeline milestones.

Dec 2, 2025 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Nov 4, 2025)

Zoetis (NYSE: ZTS) reported third quarter 2025 results on November 4, 2025, showing modest top-line growth that was offset by a meaningful reduction in full-year revenue guidance. Reported revenue was $2.4 billion, up 1% year over year, with organic operational growth of 4%. Reported net income attributable to Zoetis was $721 million, or $1.63 per diluted share, up 6% and 9% respectively. Adjusted net income was $754 million, or $1.70 per diluted share, up 9% on an organic operational basis. Growth in the U.S. segment was driven by parasiticides, diagnostics and dermatology, offset by declines in the osteoarthritis monoclonal antibodies (Librela and Solensia) and the divestiture of the medicated feed additive portfolio. International revenue grew 6% organically, led by companion animal products. The key investor takeaway is the guidance revision. Management lowered full-year 2025 revenue guidance to $9.400–$9.475 billion, with organic operational growth of 5.5%–6.5%, down from $9.450–$9.600 billion and 6.5%–8% previously, citing broader macro trends and the operating environment in the back half of the year. Organic operational adjusted net income growth was narrowed to 5.5%–7.0% from 5.5%–7.5%. Adjusted diluted EPS guidance was maintained at $6.30–$6.40, supported by cost discipline, with adjusted SG&A guidance reduced and the adjusted cost of sales ratio guided to approximately 28.3% of revenue. Management also highlighted regulatory progress, including Lenivia (a long-acting OA pain mAb for dogs) approved in Canada with EU marketing authorization expected in Q4 2025, Portela approved in the EU for cats, and a conditional FDA approval for Dectomax-CA1 against New World screwworm. Management plans an Innovation webcast on December 2, 2025. The filing states that management expects a significant approval in a major market each year for the next several years.

Nov 4, 2025 8-K

Leadership ChangesRegulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Oct 28, 2025)

Zoetis Inc. (NYSE: ZTS) filed an 8-K on October 28, 2025 reporting a board appointment rather than a financial or operational event. Under Item 5.02, the Board appointed Stephanie Tilenius as a director effective December 1, 2025, and increased the Board size from twelve to thirteen members at the same time. The filing states she was not selected under any third-party arrangement and has no reportable related-party transactions. She will join the company's standard non-employee director compensation program and sign the Company's standard indemnification agreement. Under Item 7.01, the Company also furnished a press release (Exhibit 99.1) announcing the appointment. The release highlights Ms. Tilenius's background in digital health, AI, and technology. She founded and served as CEO of Vida Health (2014-2023), a B2B chronic care platform for diabetes and obesity, and previously held senior roles at Google, PayPal, and eBay. She currently sits on the board of Seagate Technology Holdings plc. The release frames her addition as support for Zoetis's digital transformation and data-driven innovation strategy. The Item 7.01 material is furnished, not filed, so it is not subject to Exchange Act liability. For investors, this is a governance update with no disclosed impact on financial results, guidance, or capital allocation. The filing's significance lies mainly in the signal of strategic emphasis on digital and AI capabilities, which the company paired with the board expansion. Investors may want to watch whether the company follows this with concrete digital or AI initiatives in future earnings commentary.

Oct 28, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 9, 2025)

Zoetis Inc. (ZTS) has filed a current report (8-K) on October 9, 2025, primarily announcing the declaration of its fourth-quarter 2025 dividend. This dividend amounts to $0.50 per share, providing a direct return of capital to shareholders. The payment date is scheduled for December 2, 2025, with a record date of October 31, 2025. This announcement is a routine event for investors seeking income from their ZTS holdings. While this filing is limited in scope, focusing on the dividend declaration, it's important for shareholders to note the ex-dividend and payment dates to ensure they are holders of record in time to receive the payout. The company has also provided the standard disclaimer that the information is not deemed 'filed' for regulatory purposes unless specifically incorporated into other filings.

Oct 9, 2025 8-K

Material AgreementsFinancial EventsExhibits & Filings

Zoetis Inc. 8-K Report, Material Agreement (Aug 27, 2025)

Zoetis Inc. (ZTS) has announced the execution of a new $1.25 billion senior unsecured revolving credit facility, effective August 27, 2025. This facility, which matures in five years, replaces the company's previous credit agreement and provides enhanced financial flexibility with an option to increase the total commitment to $1.75 billion. The new credit line offers competitive borrowing terms, with interest rates tied to SOFR or a base rate plus an applicable margin, and includes a facility fee on commitments. The agreement's covenants focus on maintaining a maximum total leverage ratio and include standard restrictions on asset sales, mergers, and incurring priority debt, which are typical for a company of Zoetis's financial standing. The termination of the prior credit agreement, originally set to expire in December 2027, signifies a strategic move by Zoetis to optimize its capital structure and ensure access to liquidity on favorable terms. This proactive refinancing demonstrates the company's commitment to maintaining a strong balance sheet and its ability to secure robust financing arrangements to support its ongoing operations and strategic growth initiatives. Investors can view this as a positive development, indicating sound financial management and a focus on operational efficiency.

Aug 27, 2025 8-K

Other EventsExhibits & Filings

Zoetis Inc. 8-K Report, Corporate Update (Aug 18, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report detailing a significant debt financing event. On August 11, 2025, the company entered into an Underwriting Agreement to issue and sell $850 million of 4.150% Senior Notes due 2028 and $1 billion of 5.000% Senior Notes due 2035, totaling $1.85 billion in aggregate principal amount. These notes were issued under an existing indenture supplemented by a seventh supplemental indenture, with Deutsche Bank Trust Company Americas acting as the trustee. The offering was registered on Form S-3. This transaction represents a substantial capital raise for Zoetis, likely intended to fund ongoing operations, strategic initiatives, or potential acquisitions. Investors should note the specific interest rates and maturity dates for each tranche of notes, which will impact the company's future interest expense and debt repayment obligations. The filing provides detailed exhibits regarding the underwriting agreement and the indentures governing these new senior notes.

Aug 18, 2025 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Aug 5, 2025)

Zoetis reported second-quarter 2025 results on August 5, 2025, with revenue of $2.46 billion, up 4% reported and 8% on an organic operational basis, and GAAP net income of $718 million ($1.61 diluted EPS), up 15% and 18% respectively. Adjusted net income was $783 million, or $1.76 per diluted share, up 10% and 13%. Growth was led by the U.S. and International companion animal franchises, particularly Simparica Trio and dermatology products such as Apoquel and Cytopoint. Livestock was the weak spot, down 8% reported, reflecting the divestiture of the medicated feed additive portfolio and competitive pressure on Draxxin, while the Librela and Solensia osteoarthritis pain mAbs also declined in the U.S. Management raised full-year 2025 guidance across the board. Revenue is now expected at $9.450 to $9.600 billion, up from $9.425 to $9.575 billion, with organic operational growth of 6.5% to 8.0%. Adjusted diluted EPS guidance rose to $6.30 to $6.40 from $6.20 to $6.30, and adjusted net income guidance rose to $2.825 to $2.875 billion. Reported diluted EPS guidance is $5.90 to $6.00, reflecting roughly $0.40 of significant items and purchase accounting. Guidance assumes late-July foreign exchange rates and reflects enacted and announced tariffs. For investors, the quarter shows broad-based organic growth and disciplined cost management, with adjusted cost of sales falling to 26.3% of revenue from 28.3%. Reported results carry a notable gap to adjusted figures, driven by purchase accounting, restructuring, and a business process transformation program, so investors should weigh both GAAP and non-GAAP measures. The filing is furnished under Item 2.02 rather than filed, so its contents are not incorporated into Securities Act registration statements.

Aug 5, 2025 8-K

Leadership ChangesShareholder MattersExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (May 22, 2025)

Zoetis Inc. (NYSE: ZTS) filed this 8-K to report governance changes and the results of its May 21, 2025 Annual Meeting of Shareholders. Robert Scully retired from the Board effective May 21, 2025, under the company's director retirement policy, and Dr. Mark Stetter, Dean of the University of California, Davis School of Veterinary Medicine, was elected to the Board at the meeting. He will serve on the Quality and Innovation Committee. The filing contains no financial results, guidance, or operating metrics. Its investor relevance is governance and shareholder sentiment. Shareholders approved all three company-backed proposals. Holders representing 88.08% of eligible voting power attended, well above the quorum requirement. All twelve director nominees were re-elected to one-year terms, and the non-binding say-on-pay advisory vote passed, with roughly 90% of votes cast in favor (334.2 million for vs. 35.2 million against). KPMG LLP was ratified as the independent auditor for fiscal 2025. The one shareholder proposal on special shareholder meetings failed decisively, with about 86% of votes cast against (320.7 million against vs. 50.4 million for). The results point to broadly strong shareholder support for management and the Board. Director support was generally high, although Gregory Norden (about 93% for), Michael McCallister (about 96%), and Frank D'Amelio (about 94%) drew the largest against-vote totals among the nominees. The defeat of the special-meeting proposal suggests shareholders did not want to change the company's current governance terms on that issue.

May 22, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 21, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report on May 21, 2025, primarily disclosing a regular quarterly dividend declaration. The company announced a dividend of $0.500 per share for the third quarter of 2025. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders. Investors should note the payment date of September 3, 2025, and the record date of July 18, 2025, for eligibility. While this filing does not contain new financial performance data or strategic shifts, the consistent dividend payout is a positive indicator for income-focused investors. The declaration aligns with Zoetis's established practice of providing regular returns, suggesting stable operational performance and a solid cash flow generation capability. Investors seeking income from their ZTS holdings can anticipate this distribution as per the announced schedule.

May 21, 2025 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (May 6, 2025)

Zoetis (ZTS) reported first quarter 2025 revenue of $2.22 billion, up 1% on a reported basis but up 9% on an organic operational basis, which excludes foreign exchange and divestitures. Reported net income rose 5% to $631 million ($1.41 diluted EPS, up 8%). Adjusted net income was $662 million, or $1.48 per diluted share, up 4% and 7% reported and 6% organic operational. Growth was led by Companion Animal, which rose 9% organically, with Simparica Trio, Apoquel, Cytopoint, Librela and Solensia as key drivers. Livestock declined 10% on a reported basis, largely due to the divestiture of the medicated feed additive portfolio, though it rose 7% organically. Full-year 2025 guidance was mixed. Revenue guidance was raised to $9.425-$9.575 billion from $9.225-$9.375 billion, mainly reflecting foreign exchange, while organic operational revenue growth of 6-8% was maintained. Adjusted diluted EPS guidance was raised to $6.20-$6.30 from $6.00-$6.10. Management did, however, lower organic operational growth in adjusted net income to 5-7% from 6-8%, citing enacted tariffs. Reported diluted EPS guidance is $5.85-$5.95, and the adjusted cost of sales ratio was raised to roughly 28.5% from about 28.0%. The key investor takeaway is strong underlying demand in Companion Animal and International markets, offset by tariff headwinds and a higher cost base. The gap between reported and adjusted EPS guidance (about $0.35 at the midpoint) reflects purchase accounting and significant items that investors should monitor.

May 6, 2025 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Feb 13, 2025)

Zoetis Inc. (NYSE: ZTS) reported fourth quarter and full year 2024 results on February 13, 2025, and issued full year 2025 guidance. Q4 2024 revenue was $2.3 billion, up 5% reported and 6% operationally, with reported net income of $581 million ($1.29 per diluted share, up 11% and 13%). Adjusted net income was $632 million, or $1.40 per diluted share. For full year 2024, revenue reached $9.3 billion (up 8% reported, 11% operational), reported net income was $2.5 billion ($5.47 per diluted share), and adjusted diluted EPS was $5.92. Operational growth in adjusted net income was 15% for the year, and organic operational revenue growth was 12%, which excludes the October 2024 divestiture of the medicated feed additive portfolio and certain water-soluble products. The key forward-looking item is 2025 guidance: revenue of $9.225 to $9.375 billion, implying 2% to 4% operational growth and 6% to 8% organic operational growth. Reported diluted EPS is guided at $5.70 to $5.80 and adjusted diluted EPS at $6.00 to $6.10. Adjusted net income is expected to be $2.700 to $2.750 billion. Management attributes the outlook to continued demand for its franchises, with companion animal products (such as Simparica Trio, Apoquel/Cytopoint, and the Librela and Solensia osteoarthritis mAbs) driving growth, while livestock products were weaker in Q4, particularly in the U.S. Investors should note the gap between reported and adjusted EPS in 2025 (roughly $0.23 of purchase accounting and about $0.07 of significant items and deal costs), and that the divestiture is depressing reported revenue growth against the prior year. The filing is furnished under Item 2.02 and is not deemed filed under the Exchange Act.

Feb 13, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 6, 2025)

Zoetis Inc. (ZTS) has filed an 8-K report on February 6, 2025, primarily disclosing the declaration of its second quarter 2025 dividend. Investors will note that the company has declared a dividend of $0.500 per share, payable on June 3, 2025, to shareholders of record as of April 21, 2025. This announcement, made via a press release on February 6, 2025, provides a clear signal of the company's ongoing commitment to returning capital to its shareholders.

Feb 6, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Jan 13, 2025)

Zoetis Inc. (ZTS) filed this Form 8-K under Regulation FD to furnish presentation materials for management's appearance at the 43rd Annual J.P. Morgan Healthcare Conference on January 14, 2025. The filing itself contains no new financial results, guidance changes, or material events; its substance lies in the furnished slide deck (Exhibit 99.1), which is not deemed 'filed' under the Exchange Act. The presentation reports strong year-to-date performance through Q3 2024: revenue of $6.9B growing 12% operationally, adjusted net income of $2.1B up 16% operationally, and adjusted diluted EPS of $4.52 up 18% operationally. Management highlighted the Librela and Solensia franchises, the Simparica family, and the Apoquel/Cytopoint dermatology franchise as key growth drivers, and cited $1.9B in capital returned to shareholders alongside the divestiture of the Medicated Feed Additive portfolio. Looking forward, management reiterated a three-to-five-year outlook targeting mid-to-high single-digit annual revenue growth, ROIC accretion, and margin improvement, and outlined a pipeline of conditional approvals and launches for 2025, along with expansion into new therapeutic areas (renal, oncology, cardiology). Investors should note that the presentation's projections are forward-looking, rely on internal estimates and industry data, and are subject to the risks listed in the company's 10-K and 10-Q filings.

Jan 13, 2025 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 12, 2024)

Zoetis Inc. (ZTS) announced on December 12, 2024, the declaration of its first-quarter 2025 dividend. This regular dividend payment demonstrates the company's continued commitment to returning capital to shareholders, a sign of financial stability and confidence in ongoing operations. The dividend amount is set at $0.500 per share, with a payment date of March 4, 2025, for shareholders of record as of January 21, 2025. While this filing is primarily for the disclosure of the dividend, it's important for investors to note that this information is furnished under Regulation FD and is not considered "filed" for the purposes of the Securities Exchange Act of 1934. This means it doesn't automatically become part of future SEC filings unless specifically incorporated. Investors seeking further details on Zoetis's financial performance and strategic outlook should refer to other filings and communications from the company.

Dec 12, 2024 8-K

Corporate ChangesOther EventsExhibits & Filings

Zoetis Inc. 8-K Report, Change in Control (Nov 12, 2024)

On November 11, 2024, Zoetis Inc. (NYSE: ZTS) announced a set of senior leadership changes, filed under Items 5.02 and 8.01 of Form 8-K. The most significant change is the creation of a new Chief Commercial Officer role, to which Jamie Brannan, previously EVP and Group President of International Operations, Aquaculture and Global Diagnostics, has been appointed effective immediately. He will oversee commercial operations across all global markets, including the United States and all International markets, signaling an intent to consolidate commercial leadership and drive greater global collaboration as the company pursues its next phase of growth. Several executive transitions accompany the reorganization. Chief Digital & Technology Officer Wafaa Mamilli will leave in early 2025 to pursue an external opportunity, and Keith Sarbaugh, who joined in March 2023, has been promoted to EVP and Chief Digital & Technology Officer, taking responsibility for technology, digital, data and analytics strategy. Ester Banque, President of U.S. Operations, is also departing and will serve in an advisory capacity until early 2025; Jared Shriver, a nearly 20-year Zoetis veteran, has been promoted to President, U.S. Operations, reporting to Mr. Brannan. For investors, the filing contains no financial results, guidance, or quantitative disclosures. The key takeaways are management-level: the U.S. business, a major revenue contributor, is changing leadership, and the company is restructuring its commercial organization and digital leadership simultaneously. Investors will likely watch whether these changes support continued growth and whether the transitions are executed smoothly, particularly given Ms. Banque's prior role in delivering above-market U.S. performance and Ms. Mamilli's oversight of China, Brazil and precision animal health.

Nov 12, 2024 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Nov 4, 2024)

Zoetis (NYSE: ZTS) reported third quarter 2024 results on November 4, 2024 that beat the quarter on the top line and raised full-year 2024 revenue and adjusted EPS guidance. Q3 revenue was $2.39 billion, up 11% reported and 14% on an operational (FX-neutral) basis, driven by 18% U.S. companion animal growth, led by the osteoarthritis pain mAbs Librela and Solensia, Simparica Trio, and dermatology products. GAAP net income was $682 million, or $1.50 per diluted share (up 16%), while adjusted diluted EPS was $1.58 (up 16% reported, 17% operational) after excluding $34 million of purchase accounting, acquisition/divestiture, and certain significant items. Management raised full-year 2024 revenue guidance to $9.200-$9.300 billion (from $9.100-$9.250 billion), implying 10-11% operational growth, and raised adjusted diluted EPS guidance to $5.86-$5.92 (from $5.78-$5.88). Adjusted net income guidance was lifted to $2.670-$2.695 billion. Reported diluted EPS guidance is $5.33-$5.39, with the gap to adjusted EPS driven by roughly $0.29 of significant items and acquisition/divestiture costs and about $0.24 of purchase accounting. Adjusted SG&A and R&D guidance also moved higher, reflecting reinvestment alongside the top-line raise. Investors should note that the company completed the divestiture of its medicated feed additive portfolio to Phibro Animal Health on October 31, 2024, which management frames as capital reallocation toward vaccines, biologics, and genetics in livestock. Growth is strongest in U.S. companion animal products, while International growth on a reported basis was muted at 7% because of foreign exchange headwinds (-6%), and China revenue declined 12%. The financial figures in this release are unaudited, and the information is furnished under Item 2.02 rather than filed.

Nov 4, 2024 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 10, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report on October 10, 2024, primarily announcing its fourth-quarter 2024 dividend. The Board of Directors declared a dividend of $0.432 per share, demonstrating a consistent commitment to returning capital to shareholders. This dividend is scheduled to be paid on December 3, 2024, to shareholders of record as of October 31, 2024. While this filing is routine and does not contain significant operational or financial updates, the dividend declaration is a key piece of information for income-focused investors. It signals continued financial stability and management's confidence in the company's ability to generate sufficient cash flow to support its dividend payout policy.

Oct 10, 2024 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Aug 6, 2024)

Zoetis (NYSE: ZTS) reported second quarter 2024 results on August 6, 2024, delivering revenue of $2.36 billion, up 8% on a reported basis and 11% on an operational (currency-neutral) basis. Reported net income was $624 million, or $1.37 per diluted share, down 7% and 6% respectively, largely reflecting higher operating costs, R&D spending, and a swing from a prior-year $101 million gain on the sale of a pet insurance business. On a non-GAAP adjusted basis, net income rose 9% to $711 million, or $1.56 per diluted share (up 11%), and grew 18% operationally, a stronger picture of underlying profitability. Growth was led by the U.S. (up 12%) and companion animal products, notably osteoarthritis pain mAbs Librela and Solensia, Simparica Trio, and dermatology products Apoquel and Cytopoint. Management raised full-year 2024 guidance, now calling for revenue of $9.100 to $9.250 billion (9% to 11% operational growth), adjusted net income of $2.640 to $2.690 billion (13.5% to 15.5% operational growth), and adjusted diluted EPS of $5.78 to $5.88. Reported diluted EPS guidance is $5.35 to $5.45, with the gap driven primarily by roughly $80 to $90 million of certain significant items and acquisition/divestiture costs and about $110 million of purchase accounting adjustments. The guidance reflects foreign exchange rates as of late July 2024. Investors should note that international operational growth of 10% contrasted with a 6% headwind from currency, and that the company relies heavily on non-GAAP measures, which the filing reconciles to GAAP figures.

Aug 6, 2024 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Aug 1, 2024)

On August 1, 2024, Zoetis Inc. (NYSE: ZTS) announced that its Board of Directors approved a new multi-year share repurchase program authorizing the company to buy back up to $6 billion of its common stock. The program has no expiration date, does not obligate Zoetis to make any purchases, and may be terminated, increased, or decreased by the Board at any time. Repurchases may be made through open market or privately negotiated transactions. Management indicated the shares are expected to be repurchased over a period of up to four years. The authorization is described as the largest share repurchase program in Zoetis's history and is framed by management as a signal of confidence in the company's long-term outlook and continued cash flow generation. CFO Wetteny Joseph characterized the program as reinforcing the company's commitment to its value proposition, and the press release ties it to a disciplined capital allocation strategy that balances reinvestment in growth with returns to shareholders. The new authorization arrives as the prior $3.5 billion program, approved in December 2021, is expected to be completed in 2024. Investors should note that the filing is a board authorization rather than a commitment to specific purchase volumes or timing, so actual buybacks will depend on future capital needs, cash generation, and market conditions. The filing also reports 2023 revenue of approximately $8.5 billion and roughly 14,100 employees for context.

Aug 1, 2024 8-K

Leadership ChangesExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (May 24, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report detailing changes related to Heidi C. Chen's employment. Ms. Chen, previously a corporate officer, will continue with the company in a non-officer capacity until July 16, 2024, receiving her current salary and benefits. Following this date, she will transition to a non-employee consultant role until December 31, 2024. This transition includes specific compensation arrangements. Ms. Chen will receive a $350,000 consulting fee for her advisory services, contingent on her compliance with the agreement and execution of a release. She is also eligible for severance payments and benefits under the existing Zoetis Executive Severance Plan. Investors should note this is primarily an operational update regarding an executive transition, with no immediate impact on financial performance or strategic direction reported in this filing.

May 24, 2024 8-K

Leadership ChangesShareholder MattersCorporate Changes+1

Zoetis Inc. 8-K Report, Executive Changes (May 23, 2024)

Zoetis Inc. (ZTS) filed an 8-K on May 22, 2024, detailing the outcomes of its Annual Meeting of Shareholders held on May 20, 2024. Key events include the retirement of Dr. Linda Rhodes from the Board of Directors and shareholder approval of an amendment to the Restated Certificate of Incorporation to provide exculpation for certain officers, which became effective on May 22, 2024. The Annual Meeting saw high shareholder participation, with nearly 90% of voting power represented. Investors will note that all twelve director nominees were re-elected for one-year terms, and the appointment of KPMG LLP as the independent registered public accounting firm for fiscal year 2024 was ratified. The company's executive compensation program received advisory approval, indicating shareholder confidence in the current remuneration structure. However, a shareholder proposal concerning the director resignation policy was not approved.

May 23, 2024 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 22, 2024)

Zoetis Inc. (ZTS) has filed an 8-K report on May 22, 2024, primarily disclosing its third quarter 2024 dividend. The company declared a dividend of $0.432 per share, which is scheduled to be paid on September 4, 2024, to shareholders of record as of July 18, 2024. This announcement provides a clear indication of the company's commitment to returning capital to its shareholders and offers a tangible return for investors holding the stock through the specified record date.

May 22, 2024 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (May 2, 2024)

Zoetis Inc. (NYSE: ZTS) reported first quarter 2024 results on May 2, 2024, with revenue of $2.19 billion, up 10% reported and 12% on an operational (constant-currency) basis. Reported net income was $599 million, or $1.31 per diluted share, up 9% and 10% respectively. Adjusted net income, which excludes purchase accounting adjustments, acquisition-related costs and certain significant items, was $634 million, or $1.38 per diluted share, up 4% and 5% on a reported basis and 15% and 17% operationally. Growth was led by the U.S. segment, where revenue rose 16% and companion animal sales rose 25%, driven by Simparica Trio, Apoquel/Cytopoint and the osteoarthritis pain products Librela and Solensia. International revenue grew 3% reported and 8% operationally, while livestock revenue declined 5% reported and 1% operationally, with weakness in swine, sheep and cattle. Zoetis raised its full-year 2024 operational revenue growth outlook to 8.5%-10.5% and its operational adjusted net income growth outlook to 13%-15%. Revenue guidance is $9.050-$9.200 billion. Reported diluted EPS guidance is $5.34-$5.44 and adjusted diluted EPS guidance is $5.71-$5.81. Management attributed the operational increase to inflation-related price increases in Argentina and continued strength in companion animal. The guidance reflects foreign exchange rates as of late April 2024, so the reported figures remain exposed to currency movements. The company also disclosed a agreement to sell its medicated feed additive (MFA) portfolio, announced April 28, 2024, to concentrate investment on vaccines, biologics and genetic livestock programs. It also agreed to buy a manufacturing site in Melbourne, Australia. Investors will likely focus on the sustainability of companion animal growth, the drag from livestock and China, and the gap between reported and adjusted EPS.

May 2, 2024 8-K

Leadership Changes

Zoetis Inc. 8-K Report, Executive Changes (Apr 16, 2024)

Zoetis Inc. announced a significant leadership change, with Executive Vice President, General Counsel and Corporate Secretary, Heidi C. Chen, departing from her executive roles effective April 16, 2024. Ms. Chen will transition to an employee advisor role until July 16, 2024, and is expected to continue as a non-employee consultant thereafter. This departure marks a shift in the company's legal and corporate governance leadership. In response to Ms. Chen's departure, Roxanne Lagano, EVP, Chief Human Resources Officer and Global Operations, will assume the interim responsibilities of General Counsel and Corporate Secretary. Zoetis is actively searching for a permanent replacement, considering both internal and external candidates. Investors should note that Ms. Chen is eligible for severance benefits under the company's existing Executive Severance Plan and also qualifies for retirement-eligible benefits, as detailed in the company's recent Proxy Statement.

Apr 16, 2024 8-K

Leadership ChangesExhibits & Filings

Zoetis Inc. 8-K Report, Executive Changes (Apr 1, 2024)

Zoetis Inc. (NYSE: ZTS) filed a Form 8-K on April 1, 2024 to disclose a board change: Gavin D.K. Hattersley, President and CEO of Molson Coors Beverage Company, was appointed to the Board of Directors. The Board expanded from twelve to thirteen members, and Mr. Hattersley will serve on the Corporate Governance and Sustainability Committee. The filing describes the appointment as unrelated to any third-party arrangement and reports no reportable related-party transactions under Item 404(a) of Regulation S-K. The filing is a governance event rather than a financial one. It contains no earnings, guidance, financial statements, or material transactions, and the filing states no change in financial results. Mr. Hattersley's compensation will follow the non-employee director program described in Zoetis's preliminary 2024 proxy statement filed March 27, 2024, and he entered the company's standard indemnification agreement, which was previously filed as an exhibit to a 2012 Form S-1 amendment. For investors, the main significance is the addition of an experienced public-company CEO and former CFO with a background in brewing, manufacturing, and corporate development. The company frames this as support for its growth in key global markets and its strategy as a diversified animal health company. The filing does not disclose any operational impact, and the appointment should be viewed as a routine but positive governance update.

Apr 1, 2024 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Feb 13, 2024)

Zoetis Inc. (NYSE: ZTS) reported fourth quarter and full year 2023 results on February 13, 2024, and issued full year 2024 guidance. Fourth quarter revenue was $2.2 billion, up 8% on both reported and operational bases, while reported net income rose 14% to $525 million ($1.14 per diluted share). Adjusted net income of $569 million ($1.24 per diluted share) grew 6% reported and 8% per share on a reported basis, with operational growth of 6% in adjusted net income. For full year 2023, revenue reached $8.5 billion (up 6% reported, 7% operational), and reported net income was $2.3 billion ($5.07 per diluted share). Adjusted net income was $2.5 billion ($5.32 per diluted share), growing 7% operationally. Growth was led by companion animal franchises, particularly the osteoarthritis pain monoclonal antibodies Librela (dogs) and Solensia (cats), along with dermatology and parasiticide products. Management guided to full year 2024 revenue of $9.075 to $9.225 billion, representing 7% to 9% operational growth, with reported diluted EPS of $5.34 to $5.44 and adjusted diluted EPS of $5.74 to $5.84. Adjusted net income is expected to grow 9% to 11% operationally. The guidance reflects foreign exchange rates as of late January 2024. Management emphasized Librela as a path to its next billion-dollar franchise. Segment detail shows U.S. revenue up 9% in the quarter, while International revenue rose 9% reported and 8% operationally, with China notably weak, down 29% in the quarter and 16% for the year. For investors, the results show consistent operational growth and margin pressure from higher adjusted cost of sales as a percentage of revenue in the quarter, which rose to 32.9% from 31.9%. Guidance implies continued top-line expansion alongside a modest margin recovery in 2024. The 8-K furnishes the press release under Item 2.02 and is not deemed filed for Exchange Act liability purposes.

Feb 13, 2024 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 6, 2024)

Zoetis Inc. (ZTS) filed an 8-K on February 6, 2024, primarily to disclose its second quarter 2024 dividend declaration. The company announced a quarterly dividend of $0.432 per share, payable on June 4, 2024, to shareholders of record as of April 19, 2024. This announcement reflects the company's ongoing commitment to returning capital to shareholders. While this filing is limited in scope and does not contain comprehensive financial updates or material business developments, the dividend declaration signals continued confidence from management in the company's financial health and its ability to generate consistent cash flows. Investors focused on income generation and capital return policies will find this information pertinent.

Feb 6, 2024 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Dec 7, 2023)

Zoetis Inc. (ZTS) filed an 8-K on December 7, 2023, primarily announcing its first-quarter 2024 dividend. The company declared a dividend of $0.432 per share, payable on March 1, 2024, to shareholders of record as of January 19, 2024. This action signals continued confidence in the company's financial health and its commitment to returning value to shareholders.

Dec 7, 2023 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Nov 2, 2023)

Zoetis (NYSE: ZTS) reported third-quarter 2023 results on November 2, 2023, with revenue of $2.151 billion, up 7% reported and 8% on an operational (constant-currency) basis. GAAP net income attributable to Zoetis was $596 million, or $1.29 per diluted share, up 13% and 14% respectively. Adjusted net income, which excludes purchase accounting adjustments, acquisition-related costs and certain significant items, was $629 million, or $1.36 per diluted share, up 11% and 12% reported (13% and 15% operationally). Growth was led by companion animal products, which rose 11% operationally, with the U.S. up 8% and International up 8% operationally. Livestock grew 3% operationally, with U.S. livestock down 2%. The company narrowed its full-year 2023 operational growth guidance to 6.5%-7.5% for revenue and 7.5%-8.5% for adjusted net income, around the midpoint of prior ranges. Reported guidance was lowered for foreign exchange: revenue is now $8.475-$8.550 billion, reported net income $2.380-$2.415 billion, and reported diluted EPS $5.14-$5.21, while adjusted diluted EPS is $5.38-$5.43. Management highlighted the U.S. launch of Librela for dogs and continued strength in dermatology and parasiticide franchises, while noting macroeconomic pressure in China, where revenue fell 25% in the quarter. For investors, the key takeaways are steady operational growth driven by companion animals, a China headwind, and a reported-currency guidance reduction that is FX-driven rather than reflecting weaker underlying demand. The filing is furnished under Item 2.02, so it is not deemed filed under the Exchange Act. Nine-month GAAP results include a $101 million net gain on the sale of a majority interest in the pet insurance business, which boosted reported income in 2023.

Nov 2, 2023 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Oct 12, 2023)

Zoetis Inc. (ZTS) announced on October 12, 2023, that its Board of Directors has declared a quarterly dividend of $0.375 per share for the fourth quarter of 2023. This dividend underscores the company's commitment to returning capital to shareholders and reflects its ongoing financial stability and confidence in its business outlook. The dividend is scheduled to be paid on December 1, 2023, to shareholders of record as of the close of business on November 1, 2023. While this filing primarily relates to the dividend declaration, it also serves as a reminder of Zoetis's consistent dividend policy, which is a key consideration for income-focused investors.

Oct 12, 2023 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Aug 8, 2023)

Zoetis (ZTS) reported second quarter 2023 results on August 8, 2023, showing revenue of $2.2 billion (up 6% reported, 9% operationally) and GAAP net income of $671 million, or $1.45 per diluted share, up 27% and 29% respectively. Adjusted net income was $652 million, or $1.41 per diluted share, up 15% and 18% on a reported basis, and 12% operationally. The reported GAAP results were flattered by a $101 million net gain on the sale of a majority interest in its pet insurance business, which is excluded from adjusted figures. Growth was led by companion animals, with U.S. revenue up 7% and International up 11% operationally, while livestock grew 4% operationally. Management maintained its full-year 2023 operational growth guidance of 6% to 8% for revenue and 7% to 9% for adjusted net income, citing a continued expectation of strong second-half growth led by companion animals. However, reported revenue guidance was lowered to $8.500 to $8.650 billion from the prior range due to unfavorable foreign exchange rates, and reported net income guidance was updated to $2.400 to $2.460 billion, reflecting FX and the one-time pet insurance gain. Adjusted net income guidance of $2.500 to $2.550 billion and adjusted diluted EPS of $5.37 to $5.47 were updated mainly for FX effects. Key drivers included dermatology products such as Apoquel and Cytopoint, the osteoarthritis pain franchise (Librela and Solensia), and parasiticides including Simparica Trio. Investors should note that the headline GAAP growth rates are inflated by the one-time divestiture gain, so the operational adjusted growth figures provide a cleaner view of underlying performance. Gross margin on adjusted cost of sales improved to 27.6% of revenue from 30.2% a year earlier.

Aug 8, 2023 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 25, 2023)

Zoetis Inc. (NYSE: ZTS) filed this 8-K under Item 7.01 (Regulation FD) and Item 9.01 to furnish materials from its May 25, 2023 Investor Day at the New York Stock Exchange. The filing contains no new financial results, no guidance change in a formal earnings release, and no material event such as an acquisition or leadership change. Its value for investors lies in the long-term targets management presented: over the next 3-5 years, Zoetis aims to grow annual revenue at a mid-to-high single-digit rate, drive ROIC accretion, expand margins through mix shift toward higher-margin categories and operating leverage, and balance reinvestment with capital return. The materials are furnished rather than filed, so they are not subject to the liability provisions of the Exchange Act unless specifically incorporated by reference. Management framed its growth thesis around the Companion Animal business, which accounted for about 64% of 2022 revenue, and around expanding the company's billion-dollar franchises. Dermatology (2022 revenue of $1.3B) and parasiticides ($1.6B) are the core, and osteoarthritis pain, anchored by the Librela monoclonal antibody, is now expected to exceed $1B in peak sales. Pipeline opportunities in renal disease, cardiology and oncology were highlighted as new areas of investment. Management also pointed to a historical record of growing revenue about 8% annually since its 2013 IPO, adjusted EBITDA margin expansion from 28% to 42%, and a dividend that has grown roughly 20% per year. The presentation is largely forward-looking and relies on internal estimates and third-party market data from Vetnosis and others. Investors should weigh these targets against execution risks, including competition from generics (notably on Draxxin), the pace of Librela's U.S. launch, pricing power, foreign exchange, and the capital intensity of the planned manufacturing expansion. The filing reports 2022 revenue of $8.1B and adjusted diluted EPS of $4.88.

May 25, 2023 8-K

Shareholder MattersCorporate ChangesExhibits & Filings

Zoetis Inc. 8-K Report, Bylaw Amendment (May 19, 2023)

Zoetis Inc. held its 2023 Annual Meeting of Shareholders on May 18, 2023, where significant amendments to its governance structure were approved by shareholders. The most impactful change is the shareholder approval of an amendment to the Restated Certificate of Incorporation to allow for the calling of special meetings. This move, along with corresponding by-law amendments, grants shareholders more direct influence on the company's governance by providing a mechanism to convene special meetings under defined conditions. The company also saw overwhelming support for the election of its eight director nominees and the ratification of its independent auditor, KPMG LLP. Furthermore, the shareholders approved the company's executive compensation program on an advisory basis, indicating general satisfaction with the current remuneration structure. The adoption of the special meeting right, following specific procedures and limitations outlined in the amended by-laws, signifies a step towards enhanced shareholder engagement and corporate governance. Investors should monitor how these new provisions are utilized and the potential impact on future strategic decisions and shareholder activism.

May 19, 2023 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (May 11, 2023)

Zoetis Inc. (ZTS) filed an 8-K on May 11, 2023, primarily to announce its third-quarter 2023 dividend declaration. The company has declared a cash dividend of $0.375 per share, representing a continued commitment to returning capital to shareholders. This dividend is scheduled to be paid on September 1, 2023, to shareholders of record as of July 21, 2023. While this filing is limited in scope, the dividend declaration signals ongoing financial health and confidence in future performance, which is a positive signal for investors focused on income and stability.

May 11, 2023 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (May 4, 2023)

Zoetis Inc. (NYSE: ZTS) reported first-quarter 2023 results on May 4, 2023, with revenue of $2.0 billion, up 1% on a reported basis and 4% operationally (excluding foreign exchange). Reported net income was $552 million, or $1.19 per diluted share, down 7% and 6% respectively. Adjusted net income, which excludes purchase accounting adjustments, acquisition-related costs and certain significant items, was $607 million, or $1.31 per diluted share, down 3% and 1% on a reported basis, and down 3% operationally on adjusted net income. The quarter's mix was uneven. The International segment was the growth engine, with revenue up 10% operationally, led by Librela and Solensia, Simparica Trio and livestock sales in Australia. U.S. revenue fell 1%, as U.S. companion animal sales dropped 7% on distributor de-stocking, partly offset by 15% growth in U.S. livestock. Management said product sales from distributors to veterinary clinics rose about 8%, which it framed as evidence of healthy end-market demand. Gross margin compressed, with adjusted cost of sales rising to 29.2% of revenue from 28.4%, and R&D rose 16% reported. Management reaffirmed full-year 2023 guidance: revenue of $8.575 to $8.725 billion (6% to 8% operational growth), reported diluted EPS of $5.03 to $5.14 and adjusted diluted EPS of $5.34 to $5.44 (adjusted net income growth of 7% to 9% operationally). The guidance assumes FX rates as of late April 2023. The company also disclosed the purchase of a manufacturing site near Atlanta, Georgia, expected to begin operations in 2026. The 8-K is a routine earnings disclosure furnished under Item 2.02, and the press release itself is not deemed filed under Section 18 of the Exchange Act.

May 4, 2023 8-K

Earnings & ResultsExhibits & Filings

Zoetis Inc. 8-K Report, Financial Results (Feb 14, 2023)

Zoetis (NYSE: ZTS) reported fourth quarter and full year 2022 results on February 14, 2023, and issued full year 2023 guidance. Full year 2022 revenue was $8.08 billion, up 4% reported and 8% operationally (excluding FX). GAAP net income was $2.114 billion, or $4.49 per diluted share, up 5% on a per-share basis. Adjusted net income was $2.297 billion, or $4.88 per diluted share, up 11% operationally, with the adjustments primarily reflecting purchase accounting, acquisition-related costs and certain significant items (including asset impairments of $47 million for the year). Fourth quarter 2022 revenue was $2.04 billion, up 4% reported and 9% operationally. Companion Animal revenue grew 15% operationally, led by parasiticides such as Simparica Trio and dermatology products such as Apoquel and Cytopoint. Livestock was flat operationally, with cattle and poultry weakness offset by fish growth. GAAP diluted EPS was $0.99 and adjusted diluted EPS was $1.15, up 27% operationally on adjusted net income. Foreign exchange was a meaningful headwind, reducing reported growth by roughly 5 points for the quarter and 4 points for the year. For 2023, management guided to revenue of $8.575 to $8.725 billion, implying 6% to 8% operational growth, and adjusted diluted EPS of $5.34 to $5.44, implying 7% to 9% operational growth in adjusted net income. Reported diluted EPS guidance is $5.03 to $5.14. The guidance assumes FX rates as of late January, and management noted economic uncertainty. Investors will likely focus on whether the company can sustain Companion Animal momentum while Livestock remains under pressure.

Feb 14, 2023 8-K

Regulation FDExhibits & Filings

Zoetis Inc. 8-K Report, Regulation FD Disclosure (Feb 8, 2023)

Zoetis Inc. (ZTS) filed an 8-K on February 8, 2023, primarily to announce its quarterly dividend declaration. The company declared a dividend of $0.375 per share for the second quarter of 2023, maintaining its commitment to returning capital to shareholders. This declaration indicates continued financial confidence by the management, even though the filing itself does not provide detailed financial performance updates beyond this dividend information. Investors should note that the dividend payment date is June 1, 2023, with an ex-dividend date of April 21, 2023.

Feb 8, 2023 8-K

Leadership Changes

Zoetis Inc. 8-K Report, Executive Changes (Feb 7, 2023)

Zoetis Inc. (ZTS) filed an 8-K on February 7, 2023, to report the termination of Executive Vice President and Group President, Glenn David, effective February 5, 2023. The termination was for violating company policy by engaging in a consensual personal relationship and failing to disclose it. The company stated that Mr. David's conduct did not impact its consolidated financial statements or internal controls over financial reporting. Consequently, Mr. David will not receive any severance benefits or future equity vesting. William ("Chip") Dorsey, Vice President of Finance, has been appointed as the interim head of U.S. Operations and Global Diagnostics while Zoetis searches for a permanent replacement. The company emphasized that Mr. David's actions were inconsistent with Zoetis' values and policies, and a swift investigation was conducted with the assistance of independent counsel before the termination.

Feb 7, 2023 8-K

Material AgreementsFinancial EventsExhibits & Filings

Zoetis Inc. 8-K Report, Agreement Terminated (Dec 21, 2022)

Zoetis Inc. (ZTS) has announced the entry into a new five-year, $1.0 billion senior unsecured revolving credit facility, effective December 21, 2022. This new facility replaces the company's previous revolving credit agreement. A key feature is the flexibility to increase commitments to up to $1.5 billion, providing substantial financial maneuverability. The new credit facility includes provisions for interest calculations based on either a base rate or an adjusted term SOFR rate, plus applicable margins tied to Zoetis's public debt ratings, along with a facility fee on commitments. This refinancing demonstrates proactive treasury management by Zoetis, ensuring continued access to liquidity and financial flexibility for its ongoing operations and strategic initiatives. The agreement includes customary covenants, such as a maximum total leverage ratio, and allows for voluntary prepayments without penalty. The termination of the prior credit agreement, originally set to expire in December 2023, alongside the establishment of this new facility, reflects a strategic update to its funding arrangements. Investors can view this as a positive step in maintaining a robust capital structure.

Dec 21, 2022

Page 1 of 4